Lung Cancer | Specialty

Targeting Acquired Resistance Leads EGFR+ NSCLC Research Efforts

July 9th 2019

Heather Wakelee, MD, discusses the rationale and findings for two combination regimens in EGFR-mutant non-small cell lung cancer, as well as the implications for our understanding of mechanisms of resistance.

Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLC

July 4th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the available EGFR TKIs in the frontline setting for the treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC).

Entrectinib Shows Real-World PFS Benefit in ROS1+ NSCLC

July 3rd 2019

Robert C. Doebele, MD, PhD, discusses a retrospective trial comparing the efficacy of entrectinib with crizotinib in the treatment of patients with ROS1-positive non–small cell lung cancer.

Dr. Stinchcombe Discusses Differences in Toxicity Profiles Among ALK Inhibitors in NSCLC

July 2nd 2019

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the differences in toxicity profiles between brigatinib (Alunbrig) and alectinib (Alecensa) in ALK-positive non–small cell lung cancer (NSCLC).

Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

July 2nd 2019

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Dr. Lennes on Aspects of Lung Cancer Screening

June 28th 2019

Inga T. Lennes, MD, MBA, MPH, medical director, Ambulatory Services, director of clinical quality, Massachusetts General Hospital Cancer Center, discusses aspects of lung cancer screening.

Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLC

June 28th 2019

Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.

Sequencing Issues Abound as ALK+ NSCLC Armamentarium Expands

June 28th 2019

Thomas E. Stinchcombe, MD, discusses the numerous ALK inhibitors available in the treatment of ALK-positive non–small cell lung cancer, ongoing efforts to combat resistance, and sequencing challenges that have emerged.

Frontline Durvalumab/Chemo Combo Improves OS in Extensive-Stage SCLC

June 27th 2019

Durvalumab combined with standard etoposide and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with standard chemotherapy alone as a first-line treatment in patients with extensive-stage small cell lung cancer, meeting the primary endpoint of the phase III CASPIAN trial (NCT03043872).

Dr. Paik on Tepotinib in METex14-Mutated NSCLC

June 27th 2019

Paul K. Paik, MD, discussed using tepotinib—a highly selective, ATP-competitive, reversible, potent MET TKI—to treat patients with non–small cell lung cancer with MET exon 14 skipping mutations.

Dr. Ready on Promising Treatment Approaches in SCLC

June 26th 2019

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses emerging treatment approaches in small cell lung cancer (SCLC).

Borghaei Discusses Long-Term Pembrolizumab NSCLC Data, Broadening Clinical Trial Eligibility

June 26th 2019

Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.

Novel Strategies Explored to Optimize Osimertinib Treatment and Beyond in EGFR+ NSCLC

June 26th 2019

Mark G. Kris, MD, discusses the latest data with osimertinib (Tagrisso) and shared unanswered questions that remain in EGFR-positive non–small cell lung cancer.

Dr. Gainor on the PACIFIC-2 Trial in Stage III NSCLC

June 25th 2019

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the phase III PACIFIC-2 trial in stage III non–small cell lung cancer (NSCLC).

Immunotherapy in Lung Cancer

June 25th 2019

SCLC: Clinical Trials of Interest Using Novel Approaches

June 25th 2019

IMpower133 in SCLC

June 25th 2019

Treating Progressive Cases of Metastatic NSCLC

June 25th 2019

TMB and Immunotherapy in Advanced NSCLC

June 25th 2019

Maintenance Therapy for Advanced Nonsquamous NSCLC

June 25th 2019